SCH 39304 was compared with fluconazole and ketoconazole in a systemic Candida albicans infection in mice (106 CFU per mouse). Results were based on survival rates and CFU in kidneys following once-daily oral treatment of 2, 5, or 10 days duration. In normal mice, SCH 39304 (dose to reduce kidney counts by 4 log units, 0.5 mg/kg of body weight) was 3 and 200 times more active than fluconazole and ketoconazole, respectively. In immunocompromised mice (gamma irradiation, 600 rads), SCH 39304 (dose to reduce kidney counts by 4 log units, 1.3 mg/kg) was 35 and greater than 100 times more active than fluconazole and ketoconazole, respectively. In normal mice, when the infecting inoculum varied from 105 to 107 CFU, only a fivefold increase in the dose to reduce kidney counts by 4 log units was observed with SCH 39304. Excellent protection was also seen when mice were treated with a single oral dose of SCH 39304 up to 24 h prior to infection with C. albicans. Studies in a systemic C. albicans infection model indicated that SCH 39304 is equally efficacious following either oral or intravenous administration. In a systemic Aspergillusflavus infection, mice treated with SCH 39304 (5 mg/kg) survived twice as long (16 days) as those treated with fluconazole (50 mg/kg) or controls did.
In the search for less toxic, more efficacious antifungal agents that are useful parenterally as well as orally, the azoles have proved to be a significant alternative to amphotericin B. Ketoconazole, itraconazole, and fluconazole have all shown efficacy against various fungal diseases in humans. SCH 39304 is a new triazole antifungal agent with broadspectrum in vitro (2, 7, 8) and in vivo activities, and it is active orally as well as parenterally. It has excellent pharmacokinetics, is well absorbed, and has a long serum halflife in mice, rabbits, and monkeys (Sb), and it has wide tissue distribution in rabbits (Sa) . In this study, SCH 39304 was shown to be effective treatment in normal and immunocompromised mice infected with Candida albicans. Other studies have shown the efficacy of SCH 39304 in other animal models infected with C. albicans (9, 16 ), Aspergillus fumigatus (3b, lla), Cryptococcus neoformans (9, 10), Histoplasma capsulatum (5) , Coccidioides immitis (la, 3), Blastomyces dermatididis (12) , and Fusarium solani (1) . On the basis of these results, SCH 39304 may become an important drug for the treatment and prophylaxis of systemic fungal infections in patients with normal or compromised immune function.
(A preliminary report of this study was presented at the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, Calif., 23 to 26 October 1988.)
MATERIALS AND METHODS
Growth of strains. C. albicans Wisconsin (laboratory strain C 43) was grown on Sabouraud dextrose agar slants for 48 h at 28°C and was then suspended in saline and adjusted to 46% transmission at 550 nm on a spectrophotometer. The inoculum was adjusted with a hemacytometer and was confirmed by plate counts to be approximately 107 CFU/ml. Aspergillus flavus (laboratory strain ND 83) was * Corresponding author. grown on malt extract agar for 1 week at 28°C. Spores were washed from the agar surface, and the inoculum was adjusted as described above.
Mice. Harlan Sprague-Dawley, Inc. (Indianapolis, Ind.), CF-1 mice (white; male; weight, ca. 20 g) were used in these studies.
Antifungal agents. SCH 39304 was obtained from Sumitomo Pharmaceuticals Co., Ltd., Hyogo, Japan, and is identical to SM-8668 (13 and the 50% effective dose was defined as that dose which lowered kidney counts to iOs CFU, which was 4 log units below those of control mice.
A. flavus infection studies. Normal mice were infected with A. flavus by injecting 106 CFU into the tail vein. SCH 39304 or fluconazole was administered orally 4 h postinfection and once daily for 10 days. Survivors were determined each day. was shown (Fig. 2 ) by using the dose to reduce kidney counts by 4 log units (CFU per kidney). In normal mice, SCH 39304 (dose to reduce kidney counts by 4 log units, 0.45 mg/kg) was 3-fold more effective than fluconazole (dose to reduce kidney counts by 4 log units, 1.25 mg/kg) and was 200-fold more effective than ketoconazole (dose to reduce kidney counts by 4 log units, 100 mg/kg). In immunocompromised mice, SCH 39304 (dose to reduce kidney counts by 4 log units, 1 mg/kg) was 35-fold more effective than fluconazole (dose to reduce kidney counts by 4 log units, 35 mg/kg) and was at least 100-fold more effective than ketoconazole.
RESULTS
In normal mice treated for only 5 or 2 days (data not shown), the results were similar to those obtained in the 10-day treatment studies.
Effect of inoculum. The efficacy of SCH 39304 was determined in normal and immunocompromised mice that were infected with C. albicans at various inoculum levels (10', 106, and 107 CFU per mouse) and that were then treated for 10 days. In normal mice (Fig. 3) , the efficacy of SCH 39304, based on CFU per pair of mouse kidneys, was greater than that of fluconazole at each of the inoculum levels tested. In immunocompromised mice (Fig. 4) Therapeutic equivalence. Figure 6 shows the results of a study in which normal mice infected with C. albicans were treated for 4 days with SCH 39304 (0.31 to 1.0 mg/kg), which was administered either orally or intravenously (using an intravenous formulation). SCH 39304 was equally efficacious by either route, as shown by the number of CFU per kidney.
A. flavus infection. The efficacies (Fig. 7 ) of SCH 39304 (5 mg/kg) and fluconazole (5 or 50 mg/kg) were also determined in mice infected with A. flavus and treated orally for 10 days. The results showed that all mice treated with SCH 39304 (5 mg/kg) survived for 12 days postinfection. However, all mice treated with fluconazole (5 mg/kg) were dead by day 9 (similar to vehicle-treated controls), and only 50% of those treated with 50 mg of fluconazole per kg survived to day 12. 
DISCUSSION
Fungal infections pose a very serious threat to patients with impaired immune systems (4). Therefore, new antifungai drugs targeted against systemic mycoses should be evaluated for their potential efficacy in immunocompromised animal models. In the present study, the efficacy of the new triazole SCH 39304 was compared with those of fluconazole and ketoconazole in fungal infection models in both normal and immunocompromised (gamma-irradiated) mice. Treatment with all three compounds was once daily, despite differences in the pharmacokinetics of the drugs.
Richardson et al. (11) and Troke et al. (14) previously showed that fluconazole is more efficacious than ketoconazole in both normal and immunocompromised mice. In our studies, we also found fluconazole to be much more effective than ketoconazole. However, SCH 39304 was more efficacious than either fluconazole or ketoconazole in C. albicansinfected normal mice and was especially more efficacious in immunocompromised mice. The efficacy of oral SCH 39304 in immunocompromised C. albicans-infected mice was shown by increased survival rates and decreased C. albicans counts in kidneys in comparison with the results obtained with fluconazole. Ketoconazole failed to protect immunocompromised mice even at 100 mg/kg. Walsh et al. (16) showed that SCH 39304 is as effective as fluconazole alone or amphotericin B plus flucytosine in granulocytopenic rabbits with disseminated candidiasis. Many organs were completely cleared, and in other organs the numbers of organisms were reduced significantly. Perfect et al. (9) also found that SCH 39304 has excellent activity against hematogenously disseminated candidiasis in rabbits. SCH 39304 cleared the vitreous and choroid-retina and significantly reduced the numbers of organisms in the renal cortex. SCH 39304 showed equal efficacy against C. albicans in mice whether it was administered orally or intravenously, which is consistent with pharmacokinetic data showing that orally administered SCH 39304 is 100% bioavailable in mice (Sb).
SCH 39304 was also more effective than fluconazole prophylactically. When it was administered to normal mice up to 24 h prior to infection with C. albicans, SCH 39304 protected -70% of mice 5 days postinfection. Fluconazole failed to protect mice when it was administered 24 h prior to infection, but it did protect mice (40 to 100%) when treatment was given up to 6 h prior to infection. This occurred despite the fact that SCH 39304 (half-life, 5.5 h) and fluconazole (half-life, 5.1 h) have similar half-lives in mice (Sb).
SCH 39304 was also effective against systemic A. flavus infections in normal mice. In that model, SCH 39304 at 5 mg/kg was more efficacious than fluconazole at 50 mg/kg. In a murine model of systemic coccidioidomycosis, SCH 39304 was superior to fluconazole in promoting mouse survival and clearing of C. immitis from organs (la) . SCH 39304 was also more effective therapy than itraconazole and fluconazole in mice infected intracerebrally with C. immitis (3) . In a mouse model of pulmonary blastomycosis, SCH 39304 was more effective treatment than fluconazole (12) . In addition, the efficacy of treatment with SCH 39304 was similar to that with itraconazole in an athymic mouse model of chromoblastomycosis (3a) .
The mechanism of action of SCH 39304 has not yet been determined. Azole drugs are known to inhibit fungi by blocking ergosterol biosynthesis (6, 15, 17) , and SCH 39304 probably acts in this pathway. However, whether this mechanism alone or an additional mechanism could account for the increased efficacy of SCH 39304 relative to those of fluconazole and ketoconazole in immunocompromised mice is under investigation.
SCH 39304 has shown encouraging results in a number of in vivo infection studies with normal and immunocompromised animal models. These results, coupled with its good pharmacokinetic qualities, suggested that SCH 39304 is a potentially effective antifungal drug in humans. However, recent information from prolonged (18 to 24 months) toxicological studies indicates that hepatocellular adenomas and carcinomas have been observed in rats and mice. On the basis of these findings, the clinical program for SCH 39304 has been terminated.
